Odds of mortality were 2.6-3X higher in patients with detectable viral DNA; odds were even higher with multiple herpesviruses.
Japanese study confirms cognitive problems from post-transplant HHV-6B reactivation
Those with the highest viral loads suffered deficits in verbal memory and reduced quality of life.
Adding antithymocyte globulin to post transplant cyclophosphamide prophylaxis does not increase risk of HHV-6 reactivation after haploidentical hematopoietic cell transplantation
The main risk factor for HHV-6 reactivation was low absolute lymphocyte count.
Strong Evidence Linking HHV-6B To Pneumonia in Transplant Patients
Levels of mRNA transcripts indicating active infection strengthen case for pathogenic role.
Substituting letermovir for broad-spectrum ganciclovir for CMV prophylaxis did not increase HHV-6 disease in allogenic transplant patients
Investigators were surprised that the use of the less toxic CMV specific antiviral did not result in a significant increase in HHV-6-related disease.
Phase III trials suspended for T-cell therapeutic active against HHV-6
In a surprise, multi-virus cytotoxic T cell therapy trials were terminated early for failure to meet endpoints.
Part 1: Latent HHV-6 is reactivated in patients receiving CAR-T cell therapy
Investigators urge careful monitoring for HHV-6 and ciHHV-6.
Part 2: CAR-T cell therapy and its complications
Could some complications of CAR-T cell therapy be secondary to HHV-6 infection?
Part 3. HHV-6 Encephalitis in CAR-T Cell therapy
Clearly documented cases of HHV-6 encephalitis have been reported, but some are missed because they were classified as ICAN or because HHV-6 testing was not performed in patients with mental status changes.
Part 4. Might HHV-6 contribute to some cases of cytokine release syndrome, pneumonia, and cytopenias in CAR-T Cell therapy?
While unlikely to trigger the cytokine storm, HHV-6 infection may perpetuate it, and contribute directly to cytopenias and pneumonia.
Early HHV-6 specific T-cell responses by ELISpot were remarkably higher in alloHSCT patients who went on to develop clinically relevant infections
T-cell responses correlate directly with clinical symptoms, and were better predictors of HHV-6 disease than viral load or total CD3+ counts.
Increased expression of HHV-6B receptor CD134/OX40 found in DIHS/DRESS skin lesions
The severity of DIHS/DRESS cases was significantly correlated with the frequency of CD134+ cells.
Short-course foscarnet at an early stage may suppress HHV-6 reactivation following allogenic HCT
Observational study suggests that an early one-week treatment at the first sign of viral reactivation may achieve clinical benefits and avoid antiviral toxicity.
High levels of HHV-6A DNA found in blood of 52% of kidney transplant patients
HHV-6A was the most common virus identified, but was not linked to worse outcomes compared to other viral infections.
Small study finds relatively high foscarnet concentrations in CSF in HHV-6 encephalitis
CSF foscarnet concentrati.ons were very near IC50 and were followed by sharp reductions in viral load.